How to buy Addex Therapeutics stock | $8.51

Addex Therapeutics Ltd is a biotechnology business based in the US. Addex Therapeutics shares (ADXN) are listed on the NASDAQ and all prices are listed in US Dollars. Addex Therapeutics employs 27 staff and has a trailing 12-month revenue of around 0.00.

Addex Therapeutics stock price (NASDAQ: ADXN)

Use our graph to track the performance of ADXN stocks over time.

Addex Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-10.

Latest market close	$8.51
52-week range	$8.88 - $17.98
50-day moving average	$9.50
200-day moving average	$9.89
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.73

Buy Addex Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Addex Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Addex Therapeutics price performance over time

Historical closes compared with the close of $8.51 from 2021-10-14

1 week (2021-10-08)	-5.55%
1 month (2021-09-15)	-12.36%
3 months (2021-07-15)	-11.81%
6 months (2021-04-15)	-16.98%

1 year (2020-10-15)	-30.25%
2 years (2019-10-11)	N/A
3 years (2018-10-11)	N/A
5 years (2016-10-11)	N/A

Addex Therapeutics financials

Revenue TTM	$4 million
Gross profit TTM	$-6,470,057
Return on assets TTM	-35.4%
Return on equity TTM	-72.5%
Profit margin	0%
Book value	$2.89
Market capitalisation	$51.5 million

TTM: trailing 12 months

Shorting Addex Therapeutics shares

There are currently 3,325 Addex Therapeutics shares held short by investors – that's known as Addex Therapeutics's "short interest". This figure is 11.6% down from 3,762 last month.

There are a few different ways that this level of interest in shorting Addex Therapeutics shares can be evaluated.

Addex Therapeutics's "short interest ratio" (SIR)

Addex Therapeutics's "short interest ratio" (SIR) is the quantity of Addex Therapeutics shares currently shorted divided by the average quantity of Addex Therapeutics shares traded daily (recently around 3392.8571428571). Addex Therapeutics's SIR currently stands at 0.98. In other words for every 100,000 Addex Therapeutics shares traded daily on the market, roughly 980 shares are currently held short.

However Addex Therapeutics's short interest can also be evaluated against the total number of Addex Therapeutics shares, or, against the total number of tradable Addex Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Addex Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Addex Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0014% of the tradable shares (for every 100,000 tradable Addex Therapeutics shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Addex Therapeutics.

Find out more about how you can short Addex Therapeutics stock.

Addex Therapeutics share dividends

We're not expecting Addex Therapeutics to pay a dividend over the next 12 months.

Addex Therapeutics share price volatility

Over the last 12 months, Addex Therapeutics's shares have ranged in value from as little as $8.88 up to $17.98. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Addex Therapeutics's is 1.4586. This would suggest that Addex Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Addex Therapeutics overview

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. ; Indivior PLC; and The Charcot?Marie?Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Frequently asked questions

What percentage of Addex Therapeutics is owned by institutions?
Currently 8.945% of Addex Therapeutics shares are held by institutions. How many people work for Addex Therapeutics?
Latest data suggests 27 work at Addex Therapeutics. When does the fiscal year end for Addex Therapeutics?
Addex Therapeutics's fiscal year ends in December. Where is Addex Therapeutics based?
Addex Therapeutics's address is: Chemin des Mines, 9, Geneva, Switzerland, 1202 What is Addex Therapeutics's ISIN number?
Addex Therapeutics's international securities identification number is: US00654J1079 What is Addex Therapeutics's CUSIP number?
Addex Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00654J107